RxTrace

RxTrace

Search
Skip to content
  • Home
  • Contact
  • About

Tag Archives: Center for Healthcare Supply Chain Research

serialization

Estimated Rise in Serialized Drugs in The U.S. Supply Chain, 2015

August 3, 2015 Dirk Rodgers

RxTrace.com Serialization Estimate 2014.zoomIt’s August and that means it is time to check in on the progress toward full serialization of drugs in the U.S. supply chain.  This is an annual look I’ve been doing for five years now.  For my previous essays, see:

  • “Estimated Rise In Serialized Drugs In The U.S. Supply Chain”;
  • “Estimated Rise in Serialized Drugs in The U.S. Supply Chain, 2011“;
  • “InBrief: Estimated Rise in Serialized Drugs in The U.S. Supply Chain, 2012“;
  • “InBrief: Estimated Rise in Serialized Drugs in The U.S. Supply Chain, 2013“;
  • “InBrief: Estimated Rise in Serialized Drugs in The U.S. Supply Chain, 2014”.

In each essay I produced a graph of my own personal estimate Continue reading Estimated Rise in Serialized Drugs in The U.S. Supply Chain, 2015 →

Center for Healthcare Supply Chain ResearchDQSADSCSAfreeHDMApharmaceutical serializationpharmaceutical supply chainpharmaceuticalsserialization

TrackTraceRx

TrackTraceRx

About The Author

RxTrace

RxTrace.com

RxTrace is a registered trademark. All rights reserved.

…a comprehensive exploration of the intersection between healthcare supply chains, track and trace technology, standards and global regulatory compliance

  • Home
  • Contact
  • About
Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Our Privacy Policy

Site Search

Subscribe to RxTrace via Email (This is the new way to follow RxTrace and it's FREE)

Enter your email address to subscribe to RxTrace and receive notifications of new essays by email. This is the new notification method beginning in March, 2020. Feedblitz notifications will be terminated.

Full Archives

  • ▼2025 (3)
    • ►Feb(1)
      • DSCSA Compliance: Essential Steps for Manufacturers
    • ►Jan(2)
      • Regulatory Freeze Under the New Trump Administration: Implications for DSCSA Compliance
      • Countdown to May 27th: Manufacturers & Repackagers Prepare for DSCSA
  • ►2024 (2)
    • ►Oct(1)
      • DSCSA Exemptions: What You Need to Know for Compliance
    • ►Jun(1)
      • FDA's Firm Stance on DSCSA Compliance: No More Delays
  • ►2021 (9)
    • ►Aug(2)
      • FDA Official Will not extend the 2023 deadline
      • The FDA’s New Guidance for 2021 Explained
    • ►May(1)
      • FDA’s Food Safety Modernization Act (FSMA), Explained
    • ►Apr(1)
      • 2 Organizations You Need to Join to Get Ready for the DSCSA Phase II
    • ►Mar(1)
      • Does the DSCSA Affect How the Medical Marijuana Industry Is Regulated?
    • ►Feb(3)
      • EPCIS GUIDE for your organization
      • Impact of COVID-19 on DSCSA Implementation
      • Why the FDA Extended The Saleable Returns Verification from 2020 to 2023
    • ►Jan(1)
      • Drug Supply Chain Security Act, Phase II: Here’s what you MUST know
  • ►2020 (11)
    • ►Nov(1)
      • The Future of RxTrace Has Arrived
    • ►May(1)
      • FDA Provides Guidance on DSCSA Exemptions for Covid-19 PHE
    • ►Apr(1)
      • DSCSA Exemption For Public Health Emergencies
    • ►Feb(4)
      • 2021 UDI Conference Has Been Rescheduled
      • ACTION REQUIRED: RxTrace Subscriber Update
      • WHO Publishes Draft Policy Brief for Medicines Traceability Regulations
      • What Happens To The FMD In the UK After Brexit Day? Seriously, Does Anyone Know?
    • ►Jan(4)
      • How The DSCSA Is Designed To Work
      • The HHS Importation Proposed Rule
      • The Partnership for DSCSA Governance Is Up and Running
      • 2020: The View Ahead
  • ►2019 (49)
    • ►Dec(3)
      • China Sets Aggressive Date for Vaccine Traceability
      • Japan Moves To Mandate Barcodes For Drug Traceability
      • DSCSA: Industry Moves Forward
    • ►Nov(3)
      • Brazil Moves to Formalize A Phased Rollout, Starting Next October
      • DSCSA: Will 2020 Be FDA's Year To Leap Forward?
      • Russia: Rationality Makes An Appearance at the 11th Hour. Will It Matter?
    • ►Oct(4)
      • 2019 GS1 US Barcode Assessment, Extrapolated
      • China Inches Closer To Another Pharma Serialization Mandate
      • Next Week's HDA Traceability Seminar
      • FDA Inaction On Fixing The NDC Indicates Why They Should Get Out Of The Numbering Business
    • ►Sep(4)
      • No Surprise: DSCSA Verification Delay
      • Pharma Counterfeiter Strategies In a Track & Trace World
      • Russia Officially Cuts Length of Crypto-code in Half
      • GS1 US Publishes New DSCSA VRS Implementation Guide
    • ►Aug(4)
      • DSCSA Uniqueness: SNI vs SGTIN...Again
      • Can GS1 Hold Onto Drug Identification Worldwide?
      • PDSA Releases Prospectus To Prospective Governance Group Members
      • Can Trump/Azar/Sharpless Eliminate Parts of the DSCSA to Enable Importation?
    • ►Jul(4)
      • DSCSA Schedule Assessment, July 2019
      • EMVO Calls For Enforcement Of FMD/DR
      • China Commits To The Digital Future In Healthcare, Including Pharma Traceability
      • Barcodes 45, RxTrace 10
    • ►Jun(4)
      • Here We Go Again. Florida Flirts With Opening Door To Counterfeits
      • Is The FDA About To Delay Enforcement Of The Wholesaler's 2019 Mandate?
      • Meet The Latest GS1 Key: The Global Model Number (GMN)
      • China: NMPA Drug Traceability Guidance
    • ►May(3)
      • Brazil: The Anvisa 2019 Pilot Report
      • DSCSA: Historic Change To Commerce
      • PDSA Brainstorms Vision For DSCSA Governance Organization With Stakeholders
    • ►Apr(5)
      • An Aggregation 'Discussion'
      • Global Regulators Recommend Track & Trace Interoperability Features
      • Global Differences In Expiration Date Encoding
      • Blockchain And Track & Trace Models
      • PDSA's Proposal for Governance of DSCSA Phase II Interoperability
    • ►Mar(5)
      • A Serious DSCSA Governance Organizational Proposal Emerges From PDSA
      • The New GS1 Digital Link Standard
      • Russia: CRPT Posts Test Methodology For Crypto Code
      • DSCSA: What Wholesalers Want
      • DSCSA: Interoperable Data Exchange In 2023
    • ►Feb(5)
      • Barcoding Regulation For India's Domestic Drug Supply
      • FDA Hammer Comes Down On McKesson For DSCSA Violations
      • HDA Makes A Strong Case For 'Reframing' Of FDA's Draft Guidance On DSCSA Verification Systems
      • FDA Announces Start Of DSCSA Voluntary Piloting Program
      • Most Companies Will Do DSCSA Verification Wrong
    • ►Jan(5)
      • GS1's Messaging Standard For Verification Of Product Identifiers
      • FMD: Denmark Moves To Solve FMD Dilemma
      • Mixed Signals From Russia
      • EPCIS Explained
      • My Comments Regarding The New NDC Format
  • ►2018 (59)
    • ►Dec(3)
      • More Details On The Russian Crypto-Code
      • GS1 Blockchain Discussion Group Kickoff Meeting
      • FDA Gets Comments On Their Draft Q&A on DSCSA Product Identifiers
    • ►Nov(4)
      • FMD: Your Initial Upload To The EU Hub
      • How To Accept Manual Entry Of Drug Unique Identifiers
      • FDA New NDC Format Public Meeting
      • An Open Letter To The FDA: New NDC Format Public Meeting
    • ►Oct(6)
      • DSCSA: Verification Systems Draft Guidance
      • DSCSA Uniqueness: SNI vs SGTIN
      • 2018 HDA Traceability Seminar Recap
      • McKesson's DSCSA 483 Explained
      • Aggregation Under the FMD
      • FDA's Late Recommendation On Human Readable
    • ►Sep(5)
      • FDA Posts Two Final DSCSA Guidances And A Draft Product Identifier Q&A Document
      • From Serialization to Full Traceability: 2018 Outlook On Compliance
      • How Will They Delay The FMD?
      • IQPC: The Biggest Challenges Preparing For The DSCSA
      • Does the DSCSA Have A 'Spirit'
    • ►Aug(4)
      • China Posts New Draft Pharma Serialization Guidelines
      • EMVO Admits, 'Insufficient Randomisation' Warnings Can Be Ignored
      • FDA Seeks Input On The Future Format of the National Drug Code
      • Aggregation: The Achilles’ Heel of Pharma Supply Chain Operation Under A Serialization Regulation
    • ►Jul(5)
      • Personalized Medicines In A Serialized World
      • New Direction For Pharma Serialization In The Russian Federation
      • HDA Responds To FDA Waivers, Exceptions, Exemptions Draft Guidance
      • Newly Published Material From HDA and C4SCS
      • RxTrace: Year Nine
    • ►Jun(4)
      • DSCSA Makes M&A More Complex/Risky/Costly
      • DSCSA: Why FDA Will Not Mandate Blockchain, EPCIS Or Any Other Specific Technology
      • Simple, Standard, Low Cost Product Master Data Synchronization for DSCSA
      • Important New Blockchain Study Launched
    • ►May(4)
      • HDA Urges FDA To Withdraw Draft Guidance 'In Its Entirety'
      • FDA Draft Guidance: How To Apply For A Waiver, Exception or Exemption
      • FDA To Publish Key Draft Guidance Tomorrow
      • An Open Letter To Blockchain Vendors: Please Pay More Attention
    • ►Apr(6)
      • HDA Urges FDA...Please Re-Read The DSCSA
      • Data Ownership In The Track And Trace Cloud, Reprised And Updated
      • What's So Hard About Unique Identifier Verification?
      • I Receive My First Serialized Drug From My Pharmacy: Is It Right?
      • Extracting Value Beyond Compliance From Serialization
      • DSCSA: OIG Report Exposes Likely Enforcement Approach
    • ►Mar(6)
      • The 2 Most Helpful Requirements In The DSCSA
      • Newly Updated Global Serialization Regulation Map
      • DSCSA Guidance: Standardization of Data & Documentation Practices for Product Tracing
      • Interview With Four Pharma Supply Chain Thought Leaders
      • DSCSA Guidance: Definitions of Suspect and Illegitimate Product for Verification Obligations
      • FDA DSCSA Public Meeting #3: A Difference?
    • ►Feb(6)
      • The Most Head-Scratching Section Of The FMD
      • Human Readable Text Controversy
      • FMD, One Year Out
      • Unique Device Identification Questions Answered Here
      • Dispenser Perspectives On The DSCSA: An IQPC Interview
      • Wholesalers Find Troubling Results In DSCSA Barcode Assessment
    • ►Jan(6)
      • Blockchain Will Not Be Used For DSCSA Data Exchange
      • HDA Questions FDA's Authority To Mandate A Centralized System For the EDDS
      • Anti-counterfeiting Successes and Failures Around the World
      • 3 DSCSA Requirements You Can Totally Ignore
      • EDDS: The New Data Exchange Requirements
      • 2018: The Year of FDA DSCSA Public Meetings
  • ►2017 (69)
    • ►Dec(4)
      • A US Medicines Verification Organization (USMVO)? Again
      • European Medical Device and In Vitro Diagnostic Medical Device Regulations Conference
      • FDA DSCSA Public Meeting #2, Still A Gulf
      • HDA Guidelines For Bar Coding In The Pharmaceutical Supply Chain
    • ►Nov(6)
      • FDA's New DSCSA Grandfathering Guidance
      • FDA Publishes DSCSA Grandfathering Guidance Exactly 2 Years Late
      • HDA's 2017 Manufacturer Serialization Readiness Survey Results
      • FDA Speaks About DSCSA At HDA
      • HDA Traceability Seminar: RxTrace Future Topic List Explodes
      • What The TraceLink v HDA Lawsuit Teaches Us About The Value of Supply Chain Master Data
    • ►Oct(8)
      • The Fall Global GS1 Healthcare Conference
      • Tracelink vs. HDA
      • Bio/Pharma Serialization and Traceability Summit 2017
      • Opioid Epidemic: Root Cause Exposed
      • FDA DSCSA Public Meeting Q&A
      • A US Medicines Verification Organization (USMVO)?
      • Why Aren't Health Insurance Companies Interested In Pharma Traceability in the US?
      • HDA Schools FDA On DSCSA
    • ►Sep(5)
      • OPEN-SCS Announces Major Milestone
      • Does Interoperability Change In 2023?
      • Don't Miss These Back-To-Back Pharma Serialization and Tracing Events
      • The FMD Product Code
      • DSCSA: The U.S. Pharma Supply Chain Must Organize, Or Risk Failure, Again
    • ►Aug(5)
      • FDA DSCSA Public Meeting #1 Exposes Gulf In Goals
      • Identifying Trading Partners Under the DSCSA
      • How Long Until You Are Fully Serialized?
      • DSCSA Verification and Suspect Product
      • DSCSA Red Light Green Light: Verification Responses
    • ►Jul(6)
      • DSCSA Serialization Delay Eclipses Grandfathering
      • What Should FDA Pilot?
      • FDA Announces New DSCSA Pilot Program and Public Meeting Series
      • DSCSA Cascading Delays
      • DSCSA and RxTrace: The Song Remains The Same
      • FDA Delays Enforcement of DSCSA November Deadline: What It Means
    • ►Jun(5)
      • Blockchain Reigns At GS1 Connect 2017
      • Two-For-One FDA Guidance Docs
      • Serial Number Bonding
      • FDA Delays UDI and FSMA: What About DSCSA?
      • New Must-Read DSCSA Resource
    • ►May(5)
      • Brazil Publishes RDC-157 To Regulate 2017 3-Lot Pilot
      • Thank You Peggy Staver!
      • Breaking: FDA Official Offers Advice In Absence Of DSCSA Waiver Guidance
      • FDA Tea Leaves: Are They About To Delay The November Deadline?
      • Is Your Drug Too Small For The Mandated 2D Barcode?
    • ►Apr(5)
      • Will Manufacturers Have Trouble Verifying Some Drugs Next Year?
      • InBrief: Why The DSCSA Will Be Enforced Even Without FDA Guidance
      • In Absence Of FDA Guidance, Follow PDSA Recommendations
      • Ken Traub (1963 - 2017)
      • Can Anyone Buy Non-Serialized Drugs After 11-27-2019?
    • ►Mar(9)
      • How To Properly Define GTINs For Your NDCs
      • DSCSA Serialization: What Wholesalers Expect
      • My Handshake With Germany
      • Pharma Serial Number Randomization Under The Falsified Medicines Directive
      • Pharma Traceability
      • The Russia Serialization Pilot Guideline
      • The Season For Label Redesign
      • Dawn of HDA's Origin, The Key to DSCSA Compliance
      • Brand Protection: The 'No Brainer' Value, Beyond Compliance
    • ►Feb(6)
      • One Immediate Impact of President Trump On The FDA
      • ANVISA Reveals Draft Serialization Regulation and Asks For Comments
      • RxTrace to Sponsor the 2017 UDI Conference – June 7 & 8 in Baltimore, MD!
      • HDA's 2016 Serialization Readiness Survey
      • Russia Begins Its Pharma Supply Chain Pilot
      • Monitor Your Product. Manage Your Brand.
    • ►Jan(5)
      • The Intrigue Contained In The New China Drug Code
      • Serializing Product Groupings Under Global Regulations
      • First Meeting of the HDA Verification Router Service Task Force
      • DSCSA: Saleable Returns Verification
      • Brazil Gets Rational With Their New Pharma Traceability Law
  • ►2016 (63)
    • ►Dec(4)
      • NDC Nearing Its End, Afflicted by 'Identifier Failure'
      • FDA Finalizes Guidance On Suspect Product
      • Will Global Serialization Mandates Result In Less Counterfeiting?
      • Could Blockchain Technology Be Used For DSCSA Compliance?
    • ►Nov(5)
      • Drug Samples Under Global Serialization and Tracing Regulations
      • The New GS1 US DSCSA Implementation Guidance Suite
      • HDA Delivers Home Run To Record-Breaking Audience
      • Will President Trump Eliminate The DSCSA?
      • 5 Myths About The DSCSA In 2023
    • ►Oct(6)
      • China's Retreat From Pharma Serialization: Will This Become A Global Trend?
      • Is The FDA Intentionally Delaying Publication Of The Overdue DSCSA Guidance?
      • FDA Forfeits Opportunity To Guide Industry
      • Interview With Two Pharma Supply Chain Thought Leaders
      • DSCSA: Kit, Repack, Combo Product, or Just A ‘Collection’?...Again
      • The Open Serialization Communication Standard (Open-SCS)
    • ►Sep(5)
      • Brazil Officially Suspends All Remaining Serialization Deadlines Of RDC-54
      • FDA Posts DSCSA-Specific Information Sharing Agreement Template For State Agencies
      • FDA To Hold DSCSA Public Meeting
      • Serialization Mistake #1: Printing On Your Outsert
      • Proposed Pharma Serialization Regulation Progresses in Brazil
    • ►Aug(5)
      • The HDA Bar Code Quick Start Guide For Meeting The DSCSA And Other FDA Regulations
      • Product Identification And National Registration Codes
      • FDA Plans Busy Second Half of 2016 With Six DSCSA Draft Guidances Expected
      • Who Will Enforce The DSCSA 2017 Serialization Mandate?
      • China Adds Traceability Requirement To CFDA Drug Quality Management Specification
    • ►Jul(4)
      • Decommissioning Under the FMD/EUDR
      • Will Manufacturers Be Able To Grandfather Products In Their DC And 3PL? Again
      • #BlackLivesMatter Explained By A White Guy
      • Seven
    • ►Jun(4)
      • How Brexit Might Impact The Pharma Supply Chain
      • How Will The DSCSA Serialization Mandate Be Enforced After 2017?
      • DSCSA: Label Artwork Heartaches
      • FDA Speaks At GS1 Connect
    • ►May(6)
      • How RxTrace Became The Target Of A Counterfeiter
      • HDMA Responds To FDA Pilots RFC
      • More Concerns With The FMD/EUDR Big Bang Start
      • DSCSA: Kit, Repack, Combo Product, or Just A 'Collection'?
      • Important HDMA Webinar On Barcoding for DSCSA
      • Is A GS1 GTIN Really Usable As An NDC For DSCSA Compliance? Part 2
    • ►Apr(6)
      • Is A GS1 GTIN Really Usable As An NDC For DSCSA Compliance? Part 1
      • GLN: The Lowly Identifier That Could Kill The Use Of EPCIS For Pharma Regulatory Compliance
      • DSCSA Serialization Update: Where We are Now and How to Prepare for What’s Next
      • InBrief: Pharma Supply Chain Leaders, Stop Throwing Interoperability Under The Bus
      • The 2016 FDA Pilots Workshop
      • An Open Letter To The FDA, RE: Please Fix The National Drug Code Soon
    • ►Mar(5)
      • Tracking Serialization: 2016 Pharma Trace Market Trends
      • EU FMD: Aggregation Is Not Mandated, But It Will Be Necessary
      • The 2016 RxTrace U.S. Pharma Traceability Survey, Sponsored by Frequentz, Final Report
      • HDMA DMC Serves Sizzling Steak With A Small Side Of Snake Oil
      • Drug Verification: EU Vs US
    • ►Feb(9)
      • FDA Limits Ongoing Dispenser Enforcement Discretion To First Responders
      • The Many Faces Of The FDA
      • Meeting U.S. and E.U. Drug Serialization Requirements With A Single Solution
      • FDA To Hold DSCSA Pilots Workshop
      • The E.C. Officially Published The Pharma Safety Feature Delegated Act This Morning
      • U.S. Drug Wholesale Distributors Provide Direction To Manufacturers
      • FDA Considering A Delay Of A Small Part Of The UDI Rule
      • FDA Announces OMB Approval Of One DSCSA Draft Guidance
      • Announcing: The Second Edition of The Drug Supply Chain Security Act Explained
    • ►Jan(4)
      • GS1 Publishes Version 16 Of Their General Specifications ...And Why You Should Care
      • Who Is Being Harmed By Four Overdue FDA DSCSA Guidances?
      • India Posts New Deadlines (Again) For Serialization Of Drug Exports
      • 'An Open Letter To The FDA, EMA and ANVISA, RE: Who Are You Going To Punish?', Again
  • ▼2015 (66)
    • ►Dec(6)
      • RxTrace Preview of 2016
      • What The DNC Data Breach Means To The Future Of Traceability Data Repositories
      • FDA Still Receives Requests For Exemptions From 2006 Barcode Rule
      • HDMA Updates Q&A For DSCSA
      • Tell The FDA About Your Progress Toward The DSCSA Serialization Deadline, Anonymously
      • Lack Of Preparedness By CMO's Imperils Pharma Manufacturers
    • ►Nov(5)
      • FDA DSCSA Deadline Passes Quietly
      • Insufficient Transitional Measures Doom The FMD-EUDA
      • The Future of RxTrace Has Arrived
      • The Next Markets To Impose Pharma Serialization and Tracing?
      • Pay No Attention To The Enforcement Delay Unless You Are A Dispenser
    • ►Oct(7)
      • FDA Extends Dispenser Delay in DSCSA Enforcement
      • The Official Suspension of the Three-Lot Pilot in Brazil
      • Aggregation --> Chargeback Accuracy --> ROI
      • More Thoughts On FDA and ANVISA
      • FDA Posts Wholesale Distributor and 3PL License Database
      • Brazil Suspends Pharma Serialization And Tracing Requirements
      • Pharma Serialization Deadlines In Flux
    • ►Sep(4)
      • Will Manufacturers Be Able To Grandfather Products In Their DC And 3PL?
      • SAP Makes Bold Move Into Pharma Traceability
      • Again, A Closer Look At The Six-Year Record-Keeping Requirement
      • Again, Should You Off-Load Your DSCSA Obligations To Your Contract Partners?
    • ▼Aug(7)
      • An Open Letter To The FDA, EMA and ANVISA, RE: Who Are You Going To Punish?
      • The 'Unique Identifier' in the EU Delegated Act
      • Wholesaler Confusion Over DSCSA Aggregation Explained
      • Breaking News: The EC Has Published The Delegated Act
      • Stopping Cancer
      • FDA Looking For Consulting Org To Run DSCSA Pilots
      • Estimated Rise in Serialized Drugs in The U.S. Supply Chain, 2015
    • ►Jul(4)
      • I've Changed My Mind, Follow GS1's HRI Specification
      • Your Plain Old Package: Unlock Its Built-in Brand Protection Capability
      • India Proposes Serialization of Domestic Drug Supply
      • Six Years of RxTrace
    • ►Jun(6)
      • FDA Publishes New Guidance Delaying Dispenser 3T Requirements Until November 1, 2015
      • Dispensers Make Last Minute Appeal for Delay in DSCSA Deadline
      • India's Pharma Export Serialization Deadlines: April Fools!
      • FDA DSCSA Deliverables Are Bunching Up In Second Half of 2015
      • InBrief: 'The Smallest Individual Saleable Unit' In The DSCSA
      • 3PL Operation Under The DSCSA
    • ►May(5)
      • Vendor Managed Inventory Under the DSCSA
      • The Best Source Of UDI Guidance
      • Why Does ANVISA Embrace GS1 Standards, Except The Serial Number?
      • The ANVISA Unique Medicine Identifier (IUM) on Drug Packages
      • The DSCSA Product Identifier On Drug Packages
    • ►Apr(8)
      • Identification Of Pharma Cases In The U.S.
      • The Future Of RxTrace
      • ANVISA And The SSCC Controversy
      • India's Pharma Export Regulations Update And The NECC Story
      • Thank You Ron Bone!
      • Will EPCIS Event Exchange Replace EDI ASNs for DSCSA Someday?
      • DSCSA Deadline Represents A Crossed Threshold Into The SCMD Era
      • InBrief: HDMA Updates DSCSA Q&A
    • ►Mar(6)
      • Progress Toward Serialization!?
      • 2015 RxTrace U.S. Pharma Traceability Survey Results, Sponsored by Frequentz Now Available!
      • InBrief: The Rx-360 Traceability Data Exchange Architecture White Paper
      • Thank You Bob Celeste!
      • DSCSA "Serial Numbers"
      • New DSCSA Webinar Series
    • ►Feb(4)
      • When Will The DSCSA Ever Require Investments In Aggregation?
      • Is An ASN Really The Best Way to Pass Lot-Based DSCSA Transaction Data?
      • Interoperability And The DSCSA
      • RAPS Explains The 21st Century Cures Act
    • ►Jan(4)
      • DSCSA Exception Handling: A Preview of Your Next Surprise Headache
      • Pharmaceutical Traceability Forum Offers Strategic and Solution Focused Discussions to Prepare Organizations for the Upcoming Compliance Deadlines
      • The Coming Battle Over Decommissioning At The Pharmacy
      • Pharma Industry Attention Returns to Serialization
  • ►2014 (72)
    • ►Dec(7)
      • A Closer Look At Web Portals for DSCSA Transaction Data Exchange
      • FDA Postpones Enforcement of DSCSA Transaction Data Exchange Until May 1
      • FDA's DSCSA Guidance in 2014
      • FDA Posts Guidance For Wholesale Distributor and 3PL Annual Reporting
      • What will happen next? The 2015 RxTrace U.S. Pharma Traceability Survey, Sponsored by Frequentz
      • HDMA Expresses Concerns About Industry Readiness for DSCSA
      • The Coming Transition To Serialized Data
    • ►Nov(5)
      • FDA Publishes Draft Guidance For DSCSA Data Exchange
      • The DSCSA, the NDC, Inventory Management, GS1 GTINs...and Turkeys
      • Will The DSCSA Cause Drug Shortages After January 1?
      • Global Traceability Data Exchange: Troubled Waters Ahead
      • Who Is A DSCSA Repackager?
    • ►Oct(5)
      • The GS1 Healthcare US Guidance For DSCSA, Vsn 1.1
      • The Partnership For Safe Medicines Interchange 2014
      • Will GS1's EPCIS Be Used Widely For DSCSA Data Exchange?
      • The New Draft Guidance On The Effect of Section 585 of the FD&C Imposed By The DSCSA
      • Should You Off-Load Your DSCSA Obligations To Your Contract Partners?
    • ►Sep(7)
      • Will The FDA Delay The DSCSA?
      • Everything You Need To Know About UDI In One Neat Package
      • Pharma Serialization: Going Totally Global Soon
      • GS1 Healthcare US Publishes Updated Guidance For DSCSA
      • Who Is A DSCSA Dispenser?
      • The HDMA Supply Chain Product Transaction Scenarios For DSCSA
      • Is Your Drug Exempt From The Federal Drug Supply Chain Security Act? Revisited
    • ►Aug(5)
      • Pharma Supply Chain Companies Organize To Establish Global Traceability Data Exchange Architecture
      • 2014 Fall Conference Season Preview
      • FDA Posts Small Entity Compliance Guide For UDI and GUDID
      • The Case Against RFID In Pharma
      • InBrief: Estimated Rise in Serialized Drugs in The U.S. Supply Chain, 2014
    • ►Jul(7)
      • DSCSA: Special Privileges For The “Big-3″ Wholesale Distributors, Part 3
      • DSCSA: Special Privileges For The “Big-3″ Wholesale Distributors, Part 2
      • HDMA Has Updated Their EDI ASN Guidance For DSCSA, Again
      • DSCSA: Special Privileges For The "Big-3" Wholesale Distributors, Part 1
      • DSCSA: A Closer Look At The Six-Year Record-Keeping Requirement
      • 2014 RxTrace Reader Survey
      • Five Years of Pharma Supply Chain Analysis
    • ►Jun(5)
      • DSCSA: Congress Should Have Mandated Randomization
      • The FDA's Draft Guidance on Suspect Product, and Farewell Columbus
      • Product Identifier Authentication (PIA)
      • The Aggregation Hoax and PIA
      • One Goal: End Cancer.
    • ►May(6)
      • U.S. Pharma Supply Chain Complexity--Revisited
      • GS1 Ratifies Updated Versions of EPCIS and CBV
      • The Differences Between The DSCSA, FDA Rules and Guidance
      • Requesting an Extension/Exception to the U.S. FDA UDI Rules
      • The 2014 FDA DSCSA Workshop
      • UDI Deadline For Class III Medical Devices Quickly Approaching
    • ►Apr(9)
      • Just Released - The HDMA EDI ASN Guidance For DSCSA
      • Randomization—An Interview with Ken Traub—Part 5: Other Approaches
      • Randomization—An Interview with Ken Traub—Part 4: The Algorithmic Approach
      • Randomization—An Interview with Ken Traub—Part 3: Threat Analysis
      • Randomization—An Interview with Ken Traub—Part 2: Properties of Randomization
      • Randomization—An Interview with Ken Traub—Part 1: GS1 Serial Number Considerations
      • Bringing UDI and the Global UDI Database to Life
      • DSCSA: Many Questions, Few Answers
      • Is Your Drug Exempt From The Federal Drug Supply Chain Security Act?
    • ►Mar(5)
      • DSCSA: Transaction Statement
      • DSCSA: Transaction History
      • DSCSA: Transaction Information
      • The Drug Supply Chain Security Act Explained
      • The Future of Healthcare Supply Chain Security
    • ►Feb(6)
      • Decoding The FDA's DSCSA Timeline
      • DQSA: How Should Transaction Data Be Exchanged?
      • DQSA: Dancing Around The Returns Problem
      • The California Pedigree Law Is Now Officially Inoperative
      • Does The DQSA Require Manufacturers To Provide Aggregation Data? Survey Says...
      • DQSA: Did The Authors Get The Timeline Right?
    • ►Jan(5)
      • How the DQSA Will--And Won't--Protect The Supply Chain, Part 2
      • How the DQSA Will--And Won't--Protect The Supply Chain, Part 1
      • Transatlantic Alignment
      • Don't Skip The DQSA Definition of Terms Section
      • Detecting Drug Diversion With Data Analytics--An RxTrace Interview With Analytics Expert Kosta Tzavaras
  • ►2013 (103)
    • ►Dec(7)
      • This Is Not Journalism
      • Rest Up, 2014 Will Be Very Busy
      • Correction: Your Drug or Biologic Combination Product Is Probably NOT Exempt From The DQSA
      • Will The FDA Eliminate The Linear Barcode On Drugs?
      • FDA: Ready, Set, Hike!
      • Announcing The 2014 RxTrace U.S. Pharma Traceability Survey
      • Preemption: What Does It Mean?
    • ►Nov(8)
      • It's Official, President Obama Signs H.R. 3204, DQSA, Into Law
      • DQSA: The U.S. Pharma Supply Chain Must Organize, Or Risk Failure
      • DQSA: Will U.S. Pharma Distributors Mandate Aggregation Data In Phase 1?
      • DQSA: Getting To Electronic Transaction Data Exchange
      • U.S. Senate Passes H.R. 3204 With A Voice Vote
      • All Eyes On The U.S. Senate Tonight
      • Drug-Device Combo Products Under State And Federal Pedigree Laws
      • The Flaw That Must Be Addressed in H.R. 3204, The Drug Quality and Security Act
    • ►Oct(6)
      • How Smooth Will Industry Deployment of the ePedigree Laws Be? Take a Good Look At Healthcare.gov
      • InBrief: Comments on H.R. 3204 by FDA's Dr. Ilisa Bernstein at PSM Interchange 13
      • Eli Lilly: "Serialization Needs Standardization"
      • Dr Ilisa Bernstein of FDA CDER Office of Compliance To Keynote PSM Interchange
      • Will Use Of EPCIS Force Everyone To Use GS1 Identifiers?
      • California, Congress and The Choices We Are Forced To Face
    • ►Sep(7)
      • Waiting For The Senate To Act On A Track & Trace Bill, Again
      • InBrief: Important New Bicameral Draft Of A Pharma Supply Chain Security Bill
      • UDI And The Approaching End Of The NDC
      • InBrief: FDA Publishes Final UDI Rule
      • InBrief: California Proposes Breakthrough ePedigree Regulation On Drop Shipments
      • What The UDI Date Format Says About FDA's Direction
      • FDA Chooses DUNS For Unique Facility Identifier
    • ►Aug(6)
      • Working With CMOs Under California ePedigree
      • 3PL Operation Under California ePedigree
      • InBrief: 'The Smallest Package Or Immediate Container' In California
      • Vendor Managed Inventory Under California ePedigree
      • InBrief: Estimated Rise in Serialized Drugs in The U.S. Supply Chain, 2013
      • Federal Pedigree: Caught In A Web Of Politics
    • ►Jul(7)
      • Senators Propose Amendments To S. 959
      • Still Waiting For The Senate
      • Summer Writing: Steve Jobs, Bill Gates and Me
      • InBrief: CBO Estimates S. 959 Would Exceed Unfunded Mandate Threshold For Private Entities In At Least One Year
      • Fall Conference Season Preview
      • Will Generic Drug Manufacturers Serialize Their Drugs In Time?
      • Four Years Of RxTrace
    • ►Jun(28)
      • On-line Casino Bonus Us Actual Cash Bonuses
      • Topless Ladies Sign Four Pool Neon Dance Bar Bike Mens Club Stripper Peep Present
      • Hey California Board of Pharmacy: Your Time Is Running Out!
      • Greatest Online Casino Bonuses And Promotions For June 2023
      • The California ePedigree Timeline Vs. The Senate Bill Timeline
      • High 10 Us Online On Line Casino Bonuses And Promotions 2023
      • On-line Casino Bonuses ᐈ Greatest On-line On Line Casino Provides 2023
      • Summer News
      • The Means To Get Essentially The Most Out Of On Line Casino Bonuses?
      • World Brain Day 2021: Listing Videos
      • Play Online On Line Casino Games On-line Casino Uk
      • Falling Between The Cracks Of The California Pedigree Law
      • On Line Casino Presents Uk Greatest On-line Casino Bonuses
      • Palms Casino Resort Las Vegas, Nv
      • Video Exhibits Second Man Drives Incorrect Way On Roundabout During High-speed Police Chase North Wales Live
      • Lesley Manville Interview The Crown, Ageing Naturally And Enjoying Strong Ladies
      • The Most Effective Crypto And Bitcoin Casino Bonuses
      • 1win Uk On-line Casino Evaluation Games, Bets, Professionals And Cons
      • Growth Of Novice Theatre
      • Online Pageant 2020 Movies
      • Several Types Of On-line On Line Casino Bonuses
      • On Line Casino In Dc
      • Should Pharmacies Decommission EPCs Upon Dispense?
      • On-line On Line Casino Bonus Us Actual Money Bonuses
      • One Of The Best Forms Of Casino Bonuses Available In 2023 Others Information Esports Occasions Review, Analytics, Announcements, Interviews, Statistics 4cid5jijc
      • InBrief: The Pharma Track & Trace Bill Has Passed the U.S. House Of Representatives
      • InBrief: CBO Estimates H.R. 1919 Would Exceed Unfunded Mandate Threshold For Private Entities
      • The Federal Lot-Based Pedigree Before Congress
    • ►May(8)
      • The Politics Of Federal Track & Trace Legislation
      • Would A U.S. Federal Pedigree Law Require A New UFA?
      • InBrief: A Track & Trace bill Has Made It To The Senate Floor
      • Ranbaxy, FDA, FDASIA and Indian Pharma Credibility
      • InBrief: A Track And Trace Bill Has Made It To The House Floor
      • An Industry Protection Bill Concealed Under The Veil Of Patient Protection
      • House Subcommittee To Markup Track & Trace Draft Today And Tomorrow
      • California Responds To The Senate Pharma Track & Trace Discussion Draft
    • ►Apr(8)
      • The House Hearing on 'Securing Our Nation's Prescription Drug Supply Chain'
      • California's Draft Regulation on Inspections
      • California's Draft Inference Regulation
      • The New Pharma Track & Trace Discussion Draft In The Senate
      • Draft Regulations On Certifications Within California ePedigrees
      • The Board of Pharmacy Must Respond To Ideas For Making EPCIS Work
      • InBrief: Can ePedigree Be Deferred Until Mid-2016?
      • Q&A With Virginia Herold, Executive Officer, California Board Of Pharmacy
    • ►Mar(4)
      • Are Your Drugs Exempt From The California Pedigree Law?
      • The Best Laid Plans...
      • The New GS1 Healthcare US Track & Trace Guidance
      • The New Grandfathering Provisions Of The California Pedigree Law
    • ►Feb(7)
      • E-Pedigree Vendor Selection
      • New RxTrace Column in Healthcare Packaging Magazine
      • Well-Intended Report Calls For Global Track & Trace Of Pharmaceuticals
      • The Supply Chain Provisions Of The FDA Safety & Innovation Act
      • InBrief: Illegally Imported Drugs Found To Be Counterfeit...Again
      • California ePedigree Uncertainty
      • InBrief: Pharma Supply Chain Community Calls For Solutions To Security Problems
    • ►Jan(7)
      • InBrief: FDA Again Says It Plans To Publish Track & Trace Guidance By Year End
      • How Pedigrees Protect The Drug Supply: The Case Against Cumberland Distribution
      • How Should Inference Work?
      • Celebrating Martin Luther King Jr.
      • Walgreens, Automation, And Erasing Disabilities
      • Data Ownership In The Track & Trace Cloud
      • "The Shadows Of Things That MAY BE, Only" : EPCIS and California Compliance
  • ►2012 (60)
    • ►Dec(4)
      • California Board of Pharmacy Clarifies Use Of GS1 EPCIS
      • Robert J. "Bob" Bergantino (1960-2012)
      • How To Make The Semi-Centralized Track & Trace Model A Reality
      • Can HIBCC Withstand The GS1 Tide In Medical Device Identification?
    • ►Nov(6)
      • The Different Goals of Anti-Counterfeiting Technologies and Serialization
      • InBrief: Pharma Supply Chain Criminals Get Justice, Part 2
      • Pharma Anti-Counterfeiting and Serialization
      • The Significance of the Abbott, McKesson and VA Pilot
      • Will The California ePedigree Dates Slip Again?
      • More Thoughts On The Congressional Discussion Draft
    • ►Oct(7)
      • Congressional Legislation Development: Mad Libs Edition!
      • The Congressional Draft Proposal to Improve Drug Distribution Security
      • We Should Be Ashamed Of The U.S. Approach To Pharma Recalls
      • How To Maximize The ROI Of Attending A Conference
      • Could It Be The Cloud? More Thoughts On IBM's Divestiture Of Its EPCIS And E-Pedigree Suite
      • IBM Divests EPCIS and ePedigree Suite
      • InBrief: RFID and Barcode Interoperability
    • ►Sep(4)
      • InBrief: Pharma Supply Chain Criminals Get Justice
      • Should GS1 Continue Developing ePedigree Standards?
      • FDA Proposed UDI: The GUDID Database
      • InBrief: California Board of Pharmacy Webcasts
    • ►Aug(6)
      • FDA Proposed UDI: AIDC Requirements
      • FDA Proposed UDI: A Revolution In Number Assignment
      • A Quick Note About The UDI Conference September 18 & 19, 2012
      • Pelotonia 2012...180 Miles!
      • Standards and Guidance For U.S. Pharma Supply Chain Technology
      • InBrief: Estimated Rise in Serialized Drugs in The U.S. Supply Chain, 2012
    • ►Jul(5)
      • Return Of Two Classics
      • Who Will Decide Which Pedigree Model You Will Invest In?
      • The Good News About Cancer Treatments
      • Announcing, Dirk Rodgers Consulting, LLC
      • Three Years of Heat and Light
    • ►Jun(4)
      • Summer Writing
      • PDUFA Will Not Include RxTEC
      • Some People Actually WANT To Buy Counterfeit Drugs
      • The Preemption Provisions Built Into The California Pedigree Law
    • ►May(4)
      • Before You Sign Up For GDSN, Get Your Data In Order With A Data Quality Program
      • An Open Letter to GS1, RE: GDSN Marketing
      • James "Jim" Dowden (1955? - 2012)
      • The Built-in Protections Of The U.S. Pharma Supply Chain
    • ►Apr(5)
      • The Serial Number Handling In Your WMS Probably Isn't Sufficient For Pharma Serialization
      • Your GS1 Company Prefix: An Enterprise Resource
      • Should FDA Cede All Standards Development To GS1?
      • InBrief: ePedigree Models and Points of Failure
      • GS1 Standards - Betcha Can't Use Just One!
    • ►Mar(6)
      • InBrief: FDA To Publish Track & Trace Standard By Year End
      • Pharma Aggregation: How Companies Are Achieving Perfection Today
      • California Enforcement Subcommittee Moves To Require FDA SNI
      • What If RxTEC Isn't Adopted?
      • The Abrupt Surge of Interest in Serialization and ePedigree Topics
      • The Surprise Consequence of the California Pedigree Law
    • ►Feb(4)
      • Will the FDA Accept RFID for Drug Identification?
      • How Counterfeit Avastin Penetrated the U.S. Supply Chain
      • Why NOW Is The Time To Move Away From Linear Barcodes
      • Repackaging Drugs Under A Serialization Regulation
    • ►Jan(5)
      • Anatomy Of An FDA SNI
      • Depicting An NDC Within A GTIN
      • Anatomy of a GTIN
      • Updated HDMA Bar Code Guidance: A Must Read
      • Anatomy Of The National Drug Code
  • ►2011 (25)
    • ►Dec(1)
      • Could This Be Your Future Track & Trace/ePedigree Exchange Solution?
    • ►Nov(4)
      • Should Regulations Dictate Technology?
      • STEP #1: Raise Penalties For Drug Crimes To Reflect The Widespread Harm They Can Inflict
      • Why GS1 EPCIS Alone Won't Work For California Pedigree, Part 2
      • Impact of RxUSA v. HHS On Future Pedigree Legislation
    • ►Oct(3)
      • Inspecting An Electronic Pedigree
      • Why GS1 EPCIS Alone Won't Work For California Pedigree, Part 1
      • Safe Prescription Drug Reimportation: An Oxymoron
    • ►Sep(3)
      • Pharmaceutical Anti-Counterfeiting, A First-Rate New Resource
      • Discounts For PSM Interchange 2011 End Next Week
      • California Board of Pharmacy Re-awaken
    • ►Aug(1)
      • Estimated Rise in Serialized Drugs in The U.S. Supply Chain, 2011
    • ►Jul(2)
      • Pew Prescription Project: After Heparin
      • RxTrace: Sophomore Effort
    • ►Jun(2)
      • SNI's Are Not Enough In a Plateau-Based Supply Chain Security Approach
      • Illegitimate Drugs In The U.S. Supply Chain: Needle In A Haystack
    • ►May(3)
      • Plateaus of Pharma Supply Chain Security
      • U.S. Pharma Supply Chain Complexity
      • The Viability of Global Track & Trace Models
    • ►Apr(2)
      • Reliance on Trust in the U.S. Pharma Supply Chain
      • Lessons from "Drug Theft Goes Big"
    • ►Feb(1)
      • Attributes Of A Global Track & Trace Application
    • ►Jan(3)
      • GS1 Identifiers and EPC's in EDI Messages: Important New HDMA Guidance
      • Electronic Message Security and More on Certifications
      • Pharma Serialization ROI
  • ►2010 (31)
    • ►Dec(2)
      • Happy Holidays 2010
      • Do We Even Need To Mandate Drug Pedigrees Anymore?
    • ►Nov(2)
      • Writing Is Thinking. For Example, Ken Traub
      • The Future of Traceability Repositories and Inventory Management Systems
    • ►Oct(5)
      • Certifications In A California-Compliant Drug Pedigree
      • Pedigree Will Change FOB Terms
      • Partnership For Safe Medicines Interchange 2010
      • Terminology: Track and Trace, and Pedigree
      • Before You Participate in The GS1 US 2015 Readiness Program, Read This
    • ►Sep(2)
      • A Semi-Centralized, Semi-Distributed Pedigree System Idea
      • Stop Claiming that 10% of Drugs Worldwide are Counterfeit
    • ►Aug(3)
      • Masterpiece: GS1 Tag Data Standard 1.5
      • Yifan “Ivan” Shen (1962–2010)
      • Estimated Rise In Serialized Drugs In The U.S. Supply Chain
    • ►Jul(1)
      • RxTrace, One Year Retrospective
    • ►Jun(3)
      • The “Normal Distribution” Concept
      • California Pedigree Law: Historic Change to Commerce
      • Will The Pharma Supply Chain Be Able To Use Inference? Maybe Not!
    • ►May(3)
      • Inference in the Pharmaceutical Supply Chain
      • The Modern Pharmaceutical Wholesaler and the Approaching Transformation
      • Innovation and the “Authenticating Wholesaler” Idea
    • ►Apr(1)
      • RFID is DEAD…at Unit-Level in Pharma
    • ►Mar(3)
      • FDA Aligns with GS1 SGTIN For SNDC
      • So a customer demands that you use GLN’s and GTIN’s. What next?
      • WAR: GS1 Vs. HIBCC
    • ►Feb(2)
      • Supply Chain Data Synchronization and Patient Safety
      • Will The Pharma Supply Chain Find Any Value In GS1 Discovery Services?
    • ►Jan(4)
      • The Deputized Supply Chain
      • “Why the rush for GS1 standards?”
      • Charles “Chuck” Schramek (1945 – 2010)
      • New Layout for RxTrace
  • ►2009 (19)
    • ►Dec(1)
      • Who owns supply chain visibility data?
    • ►Nov(4)
      • How to Stop Pharmaceutical Cargo Theft
      • Use of GLN and GTIN for Pedigree Regulatory Compliance
      • PDMA Lawsuit Resolved?
      • What are Pedigree Laws Trying to Accomplish Anyway?
    • ►Oct(2)
      • Pedigree Models and Supply Chain Master Data
      • "The State of Healthcare Logistics"
    • ►Sep(3)
      • Master Data, Supply Chain Master Data and Instance Data
      • Who’s Responsible for Global Supply Chain Security?
      • The California Pedigree Law
    • ►Aug(4)
      • Digital Signatures
      • The Legitimate and Illegitimate Supply Chains
      • The Florida Pedigree Law
      • Subscribing to RxTrace
    • ►Jul(5)
      • GS1
      • Dangerous Doses
      • The Importance of Standards
      • Fundamental Law of Commerce
      • Welcome to rxTrace
Privacy Policy Proudly powered by WordPress

DISCLAIMER: RxTrace contains some of the personal thoughts, ideas and opinions of RxTrace. The material contained in RxTrace is not legal advice. The writers of RxTrace are not lawyers.
The reader must make their own decisions about the accuracy of the opinions expressed in RxTrace. Readers are encouraged to consult their own legal counsel
and trading partners before taking any actions based on information found in RxTrace. RxTrace is not a vehicle for communicating
the positions of any company, organization or individual other than RxTrace.

RxTrace, a comprehensive exploration of the intersection between healthcare supply chains, track and trace technology, standards and global regulatory compliance.
Contact Us | Privacy Statement
Copyright © 2009-2021 TrackTraceRx, Inc. All Rights Reserved.
RxTrace is a registered trademark of TrackTraceRx, Inc

SiteLock